Mumbai, April 28 -- Sun Pharma's $11.75 billion acquisition of US-based Organon & Co. has pushed the Indian drugmaker into the global biosimilars market and and positions it among the top 10 players in the segment, as it bets on a wave of biologics patent expiries over the next decade.

"There are $320 billion worth of biologics losing patents by 2035. If you convert this to the biosimilars market, that can be a market opportunity worth $70 billion," managing director Kirti Ganorkar told reporters in a press conference on Monday, noting that Organon's biosimilar business has grown at a compound annual growth rate of 13% over the last five years.

Sun Pharma plans to leverage Organon's commercialization platform for in-licensing and future...